Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

Appili Therapeutics reported fiscal year 2026 results, highlighting commercial momentum for LIKMEZ in the U.S. market and significant non-dilutive funding, including a US$40 million award for VXV-01 advancement. The company is focused on growing LIKMEZ sales, progressing its funded pipeline, and securing additional capital for fiscal 2027. Regulatory progress was also noted for ATI-1801, with the FDA agreeing to a scientific bridging strategy that may accelerate its path to registration.

• •Appili Therapeutics' LIKMEZ shows commercial growth in the U.S.
• •A US$40 million award supports VXV-01 development.
• •Regulatory strategy for ATI-1801 may speed up registration.